Genpax is at the forefront of addressing the global challenge of antimicrobial resistance (AMR) through its innovative platform, IDEM. This platform leverages Whole Genome Sequencing (WGS) technology to provide high-resolution, automated analysis of bacterial pathogens. IDEM enables healthcare systems, governments, and industries to integrate their efforts into a cohesive global surveillance ecosystem. By delivering results in real-time, IDEM allows clinical teams to implement prompt infection prevention interventions, significantly enhancing the ability to track and manage bacterial infections and their resistance patterns.

The IDEM platform stands out for its user-friendly interface and compatibility with existing Illumina sequencing technologies, allowing for rapid analysis without the need for specialized bioinformatics expertise. It facilitates continuous monitoring of potential outbreaks and transmission events, providing critical insights into the relationships between bacterial strains. This capability not only aids in identifying previously undetected transmission events but also supports collaborative research efforts across multiple sites, making it a vital tool for advancing infection prevention and control strategies globally.

United Kingdom

Genpax is revolutionising infectious disease investigation with IDEM, our groundbreaking surveillance tool using whole genome sequencing analysis.

IDEM uses precision genomics to uncover the true relationship between bacterial isolates, offering a comprehensive solution to strain identification and outbreak management.

IDEM not only provides unrivalled accuracy and resolution to transmission events, but also provides healthcare professionals with markers of clinical significance, signalling the need for swift containment or patient review.

Genpax

Company Details